- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.08. | Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi | ||
| 04.08. | Europe's cannabis pharmaceuticals market matures amid cautious investment | ||
| 01.08. | Eli Lilly's Mounjaro shows cardiovascular gains, but analysts underwhelmed | ||
| 01.08. | Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics | ||
| 01.08. | Cell and gene therapy market outlook strong despite technical challenges | ||
| 01.08. | BeOne Medicines' BTK degrader gains EMA PRIME designation | ||
| 31.07. | George Tidmarsh to sub in as FDA CBER head following Prasad's shock exit | ||
| 31.07. | Targeting energy expenditure: the next wave of obesity drugs | ||
| 31.07. | Targeting energy expenditure: the next wave for obesity drugs | ||
| 31.07. | Dupixent sales spur Sanofi growth, but profits fall short | ||
| 31.07. | Dr Falk Pharma and Allianthera sign agreement for ATB102 | ||
| 31.07. | African countries plan shift to healthcare funding autonomy amid aid cuts | ||
| 31.07. | Meet the company on a mission to rewrite the cell therapy paradigm from South Texas | ||
| 31.07. | Viridian and Kissei to advance veligrotug and VRDN-003 in Japan | ||
| 30.07. | GSK's speciality medicines soar while generals drop, Q2 results reveal | ||
| 30.07. | Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEO | ||
| 30.07. | ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture | ||
| 30.07. | MetrioPharm gains orphan drug status from EMA for MP1032 | ||
| 29.07. | South Korea emerges as 2025 licensing hub with 113% growth and billion-dollar deals | ||
| 29.07. | BMS and Bain Capital forge $300m immunology spinoff | ||
| 29.07. | US instils 15% tariff rate on EU for pharmaceutical products | ||
| 29.07. | Alfasigma sets stage for Jyseleca in axSpA after Phase III win | ||
| 29.07. | Re-Vana Therapeutics and Boehringer Ingelheim collaborate for eye therapies | ||
| 29.07. | Sarepta allowed to continue US Elevidys shipments | ||
| 29.07. | Ascendis Pharma's Skytrofa gains FDA approval for growth hormone deficiency |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .